Curcumin: the story so far.

By Ricky A. Sharma, A. Gescher, W. Steward. European Journal of Cancer, 2005

1,778 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Molecular understanding and modern application of traditional medicines: triumphs and trials. (2007, background): “This is particularly important as low bioavailability of the parent compound coupled with rapid intestinal metabolism dictates large doses for clinical use (Sharma et al., 2005); derivatization of the natural product is actively being pursued.”
Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. (2014, background): “For many centuries, curcumin in its crude form has been used as spice and dietary supplement as well as component of many traditional Asian medicines [9].”
Targets of curcumin (2011, background): “Based on these results, it was suggested that the low systematic bioavailability of curcumin may be due to the hydrophobic nature of the molecule, poor absorption and the metabolic biotransformation in intestine and liver [10].”
Polyphenols: Extraction Methods, Antioxidative Action, Bioavailability and Anticarcinogenic Effects (2016, background): “Other possible explanation for various capabilities of curcumin to influence several cell processes/pathways at multiple levels lies in its capacity to bind to proteins, as it has been shown to bind to at least 33 different ones [69,111].”